|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||161.11|
Buyout talks between Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) that would have resulted in the sale of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), which Valeant owns, have broken down. The negotiations could be revived, but Valeant doesn’t seem keen on resuming talks to sell its Salix business as it has already […]
With continuous effort, the average selling price of Valeant Pharmaceutical's dermatology portfolio rose 40% during 3Q16.
Here's a technical look on how to trade some of the most active stocks on the market today.